Hypertension Diagnostics, Inc.


	Hypertension Diagnostics Announces Second Quarter 2009 Results ST. PAUL, MN – February 13, 2009 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter (Q2) of fiscal year 2009 ended December 31, 2008. Revenue for Q2 2009 totaled $137,207 compared to $145,662 for Q2 2008 ending December 31, 2007, which represents a 5.8% decrease. The Company’s net loss was $191,165 for Q2 2009 or $.00 per share, compared with a net income of $165,448 for Q2 2008, or $.00 per share. Included in the net loss for Q2 2009 are total non-cash charges (mainly deferred compensation, depreciation, stock options) of $92,178. In Q2 2008, total non-cash benefits were $252,870. The decline in the Company’s stock price during Q2 2008 resulted in a negative expense for the Q2 2008 deferred compensation expense of $283,500. This caused the company to report net income, which would not have occurred without the negative deferred compensation expense in Q2 2008. The Company reported a cash balance on December 31, 2008 of $914,741. For the six month period ended December 31, 2008, total revenue was $273,719, compared to $292,014 for the six month period ended December 31, 2007, a 6.3% decrease. For the six month period ended December 31, 2008, the Company incurred a net loss of $69,560, including a non-cash benefit of $111,854, or $.00 per share, compared with a net loss of $290,760, including a non-cash charge of $64,106, or $(.01) per share, for the six month period ended December 31, 2007. “While the current quarter shows a decline in revenues from the comparable quarter in the last fiscal year, we are excited by the opportunity in the international markets, where prevention of cardiovascular disease is becoming standard of care, “ said Mark Schwartz, Chairman and CEO. “The Company has been working with new international distributors in the European and Asian markets to compete in the emerging vascular screening market where we believe our products have a compelling clinical advantage over our competitors.“
	Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2008 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-Q, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated. View PDF file: 2009 Quarter 2 Results CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Website: www.HDII.com Contact: Mark Schwartz, CEO 651-687-9999 Return to the Main HDI Newsroom Back to Top

Copyright © 2010 Hypertension Diagnostics, Inc Last revised Wednesday June 23, 2010 HDI Legal Information